Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000080255-25-000848·BridgeBio Pharma, Inc.
Schedule 13G ownership disclosure
BridgeBio Oncology Therapeutics Inc
COMMON STOCK · CUSIP: 107924102
Event date: 2025-09-30
- Filing-level shares
- 885,042
- Percent of class
- 1.1%
- T. Rowe Price Associates, Inc.
Shares: 885,042 · Class: 1.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000080255-25-000848
- Form type
- SCHEDULE 13G
- Filer
- BridgeBio Pharma, Inc.
- CIK
- CIK 1743881
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership